Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 17;13(5):1198.
doi: 10.3390/life13051198.

Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy: Is Metabolic Fear the Enemy of Logic? A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Rita Jacobs  1 , Walter Verbrugghe  1 , Karolien Dams  1 , Ella Roelant  2 , Marie Madeleine Couttenye  3   4 , Dirk Devroey  5 , Philippe Jorens  1   4
Affiliations
Review

Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy: Is Metabolic Fear the Enemy of Logic? A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Rita Jacobs et al. Life (Basel). .

Abstract

Background: Anticoagulation is recommended to maintain the patency of the circuit in continuous renal replacement therapy (CRRT). However, anticoagulation-associated complications can occur. We performed a systematic review and meta-analysis to compare the efficacy and safety of citrate anticoagulation to heparin anticoagulation in critically ill patients treated with CRRT.

Methods: Randomised controlled trials (RCTs) evaluating the safety and efficacy of citrate anticoagulation and heparin in CRRT were included. Articles not describing the incidence of metabolic and/or electrolyte disturbances induced by the anticoagulation strategy were excluded. The PubMed, Embase, and MEDLINE electronic databases were searched. The last search was performed on 18 February 2022.

Results: Twelve articles comprising 1592 patients met the inclusion criteria. There was no significant difference between the groups in the development of metabolic alkalosis (RR = 1.46; (95% CI (0.52-4.11); p = 0.470)) or metabolic acidosis (RR = 1.71, (95% CI (0.99-2.93); p = 0.054)). Patients in the citrate group developed hypocalcaemia more frequently (RR = 3.81; 95% CI (1.67-8.66); p = 0.001). Bleeding complications in patients randomised to the citrate group were significantly lower than those in the heparin group (RR 0.32 (95% CI (0.22-0.47); p < 0.0001)). Citrate showed a significantly longer filter lifespan of 14.52 h (95% CI (7.22-21.83); p < 0.0001), compared to heparin. There was no significant difference between the groups for 28-day mortality (RR = 1.08 (95% CI (0.89-1.31); p = 0.424) or 90-day mortality (RR 0.9 (95% CI (0.8-1.02); p = 0.110).

Conclusion: regional citrate anticoagulation is a safe anticoagulant for critically ill patients who require CRRT, as no significant differences were found in metabolic complications between the groups. Additionally, citrate has a lower risk of bleeding and circuit loss than heparin.

Keywords: anticoagulation; citrate; continuous renal replacement therapy; filter lifespan; heparin; metabolic complications.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Prisma flowchart.
Figure 2
Figure 2
Risk of bias.
Figure 2
Figure 2
Risk of bias.
Figure 3
Figure 3
Forest plots, funnel plots and TSA of acid-base disorders.
Figure 3
Figure 3
Forest plots, funnel plots and TSA of acid-base disorders.
Figure 4
Figure 4
Forest plots and TSA of bleeding, HIT and transfusion.
Figure 4
Figure 4
Forest plots and TSA of bleeding, HIT and transfusion.
Figure 4
Figure 4
Forest plots and TSA of bleeding, HIT and transfusion.
Figure 5
Figure 5
Forest plot of filter lifespan. Due to heterogeneity (p < 0.0001, I2 = 81.6%, H2 = 5.42), random effects model for filter lifespan was used. A significant difference of 14.52 h with 95% CI [7.22,21.83]; p < 0.0001 was found between citrate and heparin.
See this image and copyright information in PMC

References

    1. Bagshaw S.M., Berthiaume L.R., Delaney A., Bellomo R. Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: A meta-analysis*. Crit. Care Med. 2008;36:610–617. doi: 10.1097/01.CCM.0B013E3181611F552. - DOI - PubMed
    1. Ostermann M., Bellomo R., Burdmann E.A., Doi K., Endre Z.H., Goldstein S.L., Kane-Gill S.L., Liu K.D., Prowle J.R., Shaw A.D., et al. Controversies in acute kidney injury: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 2020;98:294–309. doi: 10.1016/j.kint.2020.04.020. - DOI - PMC - PubMed
    1. Oudemans-van Straaten H.M., Kellum J.A., Bellomo R. Clinical review: Anticoagulation for continuous renal replacement therapy—Heparin or citrate? Crit. Care. 2010;15:202. doi: 10.1186/cc9358. - DOI - PMC - PubMed
    1. Flanigan M.J., Pillsbury L., Sadewasser G., Lim V.S. Regional hemodialysis anticoagulation: Hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am. J. Kidney Dis. 1996;27:519–524. doi: 10.1016/S0272-6386(96)90162-6. - DOI - PubMed
    1. Fiaccadori E., Pistolesi V., Mariano F., Mancini E., Canepari G., Inguaggiato P., Pozzato M., Morabito S. Regional citrate anticoagulation for renal replacement therapies in patients with acute kidney injury: A position statement of the Work Group “Renal Replacement Therapies in Critically Ill Patients” of the Italian Society of Nephrology. J. Nephrol. 2015;28:151–164. doi: 10.1007/s40620-014-0160-2. - DOI - PubMed

LinkOut - more resources